Previous Close | 3.5300 |
Open | 3.4900 |
Bid | 2.7100 x 4000 |
Ask | 3.9500 x 900 |
Day's Range | 3.2800 - 3.5643 |
52 Week Range | 1.9100 - 10.5000 |
Volume | |
Avg. Volume | 673,516 |
Market Cap | 406.41M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for OABI
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. Nevertheless, they could yield tremendous profitability if they come through. Another factor that benefits high-risk, high-reward biotech stocks centers on the underlying sector’s permanent
EMERYVILLE, Calif., March 09, 2023--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
For investors, the stock market is always a game of risk and reward, and no segment exemplifies that better than the penny stocks. Defined as stocks trading at a price of less than $5, the pennies bring an ultra-low cost of entry to the table, along with a powerful potential for strong gains. At these low initial prices, even a small incremental increase in share price will quickly translate into a high-percentage gain on the initial investment – and for penny stocks’ fans, gains of 200% or even